Ramacciotti E, Agati LB, Calderaro D, et al. - Thromboprophylaxis with rivaroxaban 10 mg/day for 35 days in patients at high risk discharged post-hospitalisation due to COVID-19 was found to result in improved clinical outcomes in comparison to no extended thromboprophylaxis.

• In this open-label, multicentre, randomised trial, 320 patients hospitalised with COVID-19 at increased risk for venous thromboembolism were randomized to receive, at hospital discharge, rivaroxaban (n=160 [50%]) or no anticoagulation (n=160 [50%]) for 35 days.

• The primary efficacy outcome was a composite of symptomatic or fatal venous thromboembolism, asymptomatic venous thromboembolism on bilateral lower-limb venous ultrasound and CT pulmonary angiogram, symptomatic arterial thromboembolism, and cardiovascular death at day 35.

• In the rivaroxaban and no anticoagulation groups, the primary efficacy outcome occurred in 3% and 9% of the patients, respectively (relative risk 0·33, 95% CI 0·12–0·90).

• In either study group, no major bleeding occurred.

• In the rivaroxaban group, allergic reactions developed in 1%.